Tumor Markers in Lung Cancer: DCAMLK-1LK-1

Not Applicable

Completed

• Conditions: Lung Cancer; Smoking
• Interventions: Other: Measure DCAM levels in blood; Other: DCAM levels in blood

• Registration Number: NCT01578018
• Lead Sponsor: University of Oklahoma

Brief Summary

DCAMLK1 is a Ca2+ - ca/modulin (CaM) - dependent protein kinase that is a marker of stem cells in colonic crypts. Mutations within the stem cell population are thought to be responsible for the development of most colorectal carcinomas and studies have shown that DCAMLK1 is highly expressed in these tumors. Since the lung is an embryological development of the foregut, the investigators speculate that DCAMLK1 will also be upregulated in lung cancers.

The aim of this pilot study is to measure DCAMLK1 levels in the blood of patients with suspected malignant and benign lung diseases, and to correlate DCAMKL1 levels with smoking status.

Detailed Description

In the investigators' preliminary study DCAMKL1 antigen was detected not only in malignant tissue, but also in BAL fluid from patients with benign lung disease. This suggests that DCAMKL1 expression might be induced by smoking or benign lung diseases. To examine this hypothesis, the investigators will compare DCAMLK1 expression in blood from patients with lung cancer to controls who are current or former smokers with benign lung disease.

Previous work has showed that DCAMLK1 is not detectable in the blood of healthy non smoking individuals. To determine whether smoking and or pulmonary inflammation induce DCAMLK1 expression, the investigators will obtain serum samples from 20 control patients with lung disease who are seen in the Chest Clinic at the Oklahoma City VAMC. Smoking histories will be obtained for all participants and DCAMLK1 levels will be correlated with smoking status.

Study Timeline

• Study Start: 2011-12
• Study First Submitted: 2012-04-11
• Study First Submitted QC: 2012-04-12
• Study First Posted: 2012-04-16
• Primary Completion: 2012-07
• Study Completion: 2012-07
• Status Verified: 2012-08
• Last Update Submitted: 2012-08-08
• Last Update Posted: 2012-08-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

• >45 years of age

Exclusion Criteria

• Unable to provide informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lung Cancer	Measure DCAM levels in blood	Diagnostic
Lung Disease	DCAM levels in blood	Diagnostic

Primary Outcome Measures

Name	Time	Method
Tumor Markers in Lung Cancer:	6 months	DCAMLK-1LK-1 levels will be measured in the blood of patients with Lung Cancer and compared to that of controls with other lung diseases.

Trial Locations

Locations (1)

VAMC-OKC; 🇺🇸 Oklahoma City, Oklahoma, United States